亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial

医学 曲妥珠单抗 胃食管交界处 肿瘤科 内科学 癌症 腺癌 胃腺癌 乳腺癌
作者
Lin Shen,Pei Chen,Jun Lü,Yueping Wan,Yang Zheng,Fayin Ye,Jingcheng Yang,Y. Liu,Hongming Pan,Hui Chen,Meili Sun,Qiang Fan,Yuan Yang,Ken Chen,Ziyong Sun,He Tian,Xianjiang Ye,Zhi Peng
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1542-S1543 被引量:1
标识
DOI:10.1016/j.annonc.2023.10.307
摘要

For pts with HER2-positive advanced/recurrent GC/GEJA in China, treatment options are limited. T-DXd is a HER2-directed antibody-drug conjugate; T-DXd 6.4 mg/kg is approved in the US, EU, Japan, South Korea and Singapore for treatment of locally advanced/metastatic GC/GEJA in adults who received a prior trastuzumab-based regimen. In DESTINY-Gastric01 (DG01), T-DXd showed significant improvements in response rates and overall survival (OS) versus standard therapies in pts from Japan/South Korea with HER2-positive advanced GC/GEJA. In this open-label, single-arm, phase 2 trial (NCT04989816), Chinese pts with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+ by central laboratory) advanced GC/GEJA who had received ≥2 prior treatment regimens, including a fluoropyrimidine and a platinum agent, received T-DXd 6.4 mg/kg intravenous infusion once every 3 weeks. Primary endpoint was confirmed objective response rate (ORR) by independent central review (ICR) per RECIST v1.1. Secondary endpoints included investigator-assessed (INV) confirmed ORR, INV duration of response (DOR), INV progression-free survival (PFS), and OS. Safety and tolerability were assessed. At data cutoff (Jun 16, 2023), 95 pts were enrolled (intent-to-treat [ITT]); 73 pts were confirmed HER2-positive (IHC 3+ or IHC 2+/ISH+; full analysis set [FAS]) by central laboratory. In the FAS, 65.8% of pts were <65 years of age, 72.6% were IHC 3+ and primary tumor location in 30.1% of pts was GEJ. Efficacy and safety data are shown in table. This primary analysis of T-DXd in Chinese pts with HER2-positive advanced GC/GEJA demonstrated clinically meaningful and durable objective responses, with a manageable safety profile, and is consistent with results from DG01.Table: 172PFASN=73Median prior lines of therapy, n (range)2 (2–6)Median duration of follow-up, months (Q1, Q3)8.0 (6.0, 13.2)ICR confirmed ORR, n (%)21 (28.8)INV confirmed ORR, n (%)26 (35.6)Median DOR, months (95% confidence interval [CI])7.9 (4.6, 8.8)Median PFS, months (95% CI)5.7 (4.0, 6.8)Median OS, months (95% CI)10.2 (7.5, 14.3)ITTN=95Median T-DXd duration, months (range)3.4 (0.4,14.5)Grade (G) ≥3 adverse events (AE), n (%)70 (73.7)Discontinued treatment due to AEs, n (%)12 (12.6)Discontinued treatment due to COVID-19-associated AEs, n (%)5 (5.3)Adjudicated drug-related interstitial lung disease/pneumonitis, n (%)3 (3.2)G12 (2.1)G21 (1.1)G3–G50 Open table in a new tab
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
和谐远望发布了新的文献求助10
1秒前
5秒前
量子星尘发布了新的文献求助50
10秒前
11秒前
小二郎应助科研通管家采纳,获得10
15秒前
NexusExplorer应助科研通管家采纳,获得10
16秒前
16秒前
lin完成签到 ,获得积分10
27秒前
32秒前
阿亞完成签到,获得积分10
43秒前
不知道取啥名完成签到 ,获得积分10
48秒前
52秒前
标致荔枝完成签到,获得积分10
54秒前
56秒前
啊啊啊啊啊啊啊啊啊啊完成签到 ,获得积分10
59秒前
半青一江完成签到 ,获得积分10
1分钟前
001完成签到,获得积分10
1分钟前
1分钟前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
头孢西丁完成签到 ,获得积分10
1分钟前
隐形曼青应助科研通管家采纳,获得10
2分钟前
Akim应助科研通管家采纳,获得10
2分钟前
上官若男应助科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
量子星尘发布了新的文献求助10
3分钟前
3分钟前
向日葵的微笑完成签到,获得积分10
3分钟前
3分钟前
3分钟前
领导范儿应助带虾的烧麦采纳,获得10
3分钟前
张杠杠完成签到 ,获得积分10
3分钟前
Zhou完成签到,获得积分10
3分钟前
万能的悲剧完成签到 ,获得积分10
3分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520735
关于积分的说明 11204640
捐赠科研通 3257493
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613